We first identified the expression profile of CD47 using GEPIA2, which showed significant upregulation of CD47 in several cancer types including cervical squamous cell carcinoma (CESC), colon adenocarcinoma (COAD), diffuse large B‐cell lymphoma (DLBC), acute myeloid leukemia (LAML), ovarian carcinoma (OV), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) (p < 0.05, Figure 1A). This evidence concerns the gene CD47 and uterine carcinosarcoma.